Targeted Therapy for KRAS Mutant Non-Small Cell Lung Cancer

Ola Gaber¹, Ihab Eldesouki^1*, Mohamed Magdy², Mohamed Rahouma³, John Morris, C.¹ & Nagla Abdel Karim¹

¹Department of Hematology-Oncology, University of Cincinnati, USA
²Pediatric Oncology Department, Hospital, Cairo, Egypt
³Surgical Oncology Department, National Cancer Institute, Cairo University, Egypt

Dr. Ihab Eldesouki, Department of Hematology-Oncology, University of Cincinnati, USA.

Keywords: K-RAS; Therapy; Lung Cancer; Mutation; Survival

Abstract

Approximately one third of non-small-cell lung cancer (NSCLC) cases carry activating point mutations in the KRAS oncogene. Its protein product is known as the K-Ras protein, that is a 188-amino acid protein with 21.6 kDa molecular weight. The K-Ras is a major player in activating multiple cellular signaling cascades through the RAS/MAPK pathway, that can result in transformation and tumor progression.

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).